1. Home
  2. LQDA vs PCH Comparison

LQDA vs PCH Comparison

Compare LQDA & PCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LQDA

Liquidia Corporation

HOLD

Current Price

$34.21

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Logo PotlatchDeltic Corporation

PCH

PotlatchDeltic Corporation

HOLD

Current Price

$40.05

Market Cap

3.0B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
LQDA
PCH
Founded
2004
1903
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
3.0B
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
LQDA
PCH
Price
$34.21
$40.05
Analyst Decision
Strong Buy
Hold
Analyst Count
10
6
Target Price
$37.40
$45.67
AVG Volume (30 Days)
1.1M
537.1K
Earning Date
11-03-2025
01-26-2026
Dividend Yield
N/A
4.51%
EPS Growth
N/A
312.61
EPS
N/A
0.82
Revenue
$69,216,000.00
$1,115,571,000.00
Revenue This Year
$994.17
$3.66
Revenue Next Year
$169.25
$1.27
P/E Ratio
N/A
$48.68
Revenue Growth
343.41
5.40
52 Week Low
$11.26
$36.82
52 Week High
$36.41
$48.12

Technical Indicators

Market Signals
Indicator
LQDA
PCH
Relative Strength Index (RSI) 55.31 51.39
Support Level $33.45 $39.02
Resistance Level $36.60 $40.35
Average True Range (ATR) 1.41 0.93
MACD -0.25 0.01
Stochastic Oscillator 47.88 39.24

Price Performance

Historical Comparison
LQDA
PCH

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About PCH PotlatchDeltic Corporation

PotlatchDeltic Corp is a REIT that owns and manages forestland in Alabama, Arkansas, Idaho, Minnesota, and Mississippi. Potlach operates in three segments. The timberlands segment covers the planting and harvesting of trees, as well as the construction and maintenance of roads. The wood products segment manufactures and distributes lumber, plywood, and other wood products. The real estate segment covers the sales generated from company-owned timberlands, as well as commercial and residential properties. The timberlands and the wood product segments combined drive the majority of the company's revenue.

Share on Social Networks: